Briefing: Argo's Marlborough Move
PHOTO/COURTESY
A woman wearing ARGO's ReWalk exoskeleton suit walks a flight of stairs.
ARGO Medical Technologies, an Israeli-based manufacturer of medical technology, announced this month it will establish its U.S. headquarters in Marlborough, bringing with it up to 40 jobs. The announcement was made by Gov. Deval Patrick and officials of the Massachusetts Life Sciences Center at an industry conference in Boston.
Where will the company be located?
The company will move into space at 33 Locke Dr. in Marlborough, just off the southbound site of Interstate 495 between Route 20 and Interstate 290.
When will they move in?
Company spokeswoman Kristen Cullen said ARGO plans to move into the Locke Drive building when the company lease begins Nov. 15.
What does ARGO make?
ARGO's product, the ReWalk, is an exoskeleton suit that enables people with lower-limb disabilities, especially paraplegics, to stand up and walk without assistance. The company's founder, Amit Goffer, is himself a quadriplegic, which inspired him to invent the device. During the announcement of the Marlborough plans, Theresa Hannigan, a former U.S. Army sergeant who served in Vietnam who has been paralyzed for two years due to a disease she contracted while on active duty, demonstrated the ReWalk. The product is available at rehabilitation centers in the U.S. and is awaiting clearance from the U.S. Food and Drug Administration for personal use.
Why did ARGO select Massachusetts for its headquarters?
Company officials cited the state's "strong commitment to the life sciences industry. The Massachusetts Life Sciences Center, the quasi-public agency that's leading the Patrick administration's push to grow the industry, is charged with investing $1 billion to create jobs and support scientific research in the area.
How successful has the life sciences center been in attracting companies to Massachusetts?
Over the past four years, the agency has brought more than 25 companies here, said its spokesman, Angus McQuilken. Among them: French-based Ipsen, which set up shop in Milford and, earlier this year, announced plans for a $45-million expansion at that facility. In Milford, Ipsen develops new therapies and makes proteins used in the treatment of hemophilia. It employs 150 at the site.
Read more
Life Sciences Firm Picks Marlborough As Its HQ
Briefing: New England Compounding Center
WBJ Web Partners
Most Recent
Most Recent
0 Comments